J A Liu Yin
Overview
Explore the profile of J A Liu Yin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakhinia E, Farahangpour M, Tholouli E, Liu Yin J, Hoyland J, Byers R
J Clin Pathol
. 2006 Apr;
59(10):1059-65.
PMID: 16644881
Background: Gene signatures (Indicator genes) in bone marrow that provide more precise prognostication in haematological malignancy have been identified by microarray expression studies. It would be beneficial to measure these...
2.
Osborne D, Frost L, Tobal K, Liu Yin J
Bone Marrow Transplant
. 2005 May;
36(1):67-70.
PMID: 15908982
Relapse postautograft in acute myeloid leukaemia (AML), may in part arise from leukaemia cells present in the bone marrow (BM) inoculum, and the level of minimal residual disease (MRD) in...
3.
Geissler K, Liu Yin J, Ganser A, Sanz M, Szer J, Raghavachar A, et al.
Ann Hematol
. 2003 Oct;
82(11):677-83.
PMID: 14530872
Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) administered after acute myeloid leukemia (AML) chemotherapy (CT) failed to shorten the time of transfusion-dependent thrombocytopenia in a previous study. In...
4.
Liu Yin J
Best Pract Res Clin Haematol
. 2002 May;
15(1):119-35.
PMID: 11987920
Relapse remains the main cause of treatment failure in acute myeloid leukaemia (AML). Studies to date suggest that monitoring of minimal residual disease (MRD) in AML is useful in identifying...
5.
Le Maitre C, Byers R, Liu Yin J, Hoyland J, Freemont A
J Clin Pathol
. 2001 Sep;
54(9):730-3.
PMID: 11533086
Aims/background: The advent of new treatments for haematological malignancies has led to the need for a correlation between cytogenetic and morphological abnormalities. This study aimed to achieve this by the...
6.
Liu Yin J, Wheatley K, Rees J, Burnett A
Br J Haematol
. 2001 May;
113(3):713-26.
PMID: 11380463
This aim of the acute myeloid leukaemia (AML)-R trial was to compare sequential (Seq) ADE (cytarabine, daunorubicin, etoposide) with standard (Std) ADE as remission re-induction treatment and to assess any...
7.
8.
Liu Yin J, Adams J, Brereton M, Hann A, Harrison B, Briggs M
Br J Haematol
. 2000 May;
108(4):743-6.
PMID: 10792278
Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) can stimulate megakaryopoiesis in vitro in some myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) patients. We assessed PEG-rHuMGDF combined with...
9.
Borg A, Burgess R, Green L, Scheper R, Liu Yin J
Br J Haematol
. 2000 Jan;
108(1):48-54.
PMID: 10651723
The in vitro intracellular daunorubicin accumulation (IDA) of blast cells from 69 patients with newly diagnosed acute myeloid leukaemia (AML) was correlated with the expression and functional activity of the...
10.
Tobal K, Newton J, Macheta M, Chang J, Morgenstern G, Evans P, et al.
Blood
. 2000 Jan;
95(3):815-9.
PMID: 10648391
One of the most common translocations in acute myeloid leukemia (AML) is the t(8;21), which produces the fusion gene AML1-MTG8. We have developed a sensitive competitive reverse transcriptase-polymerase chain reaction...